| Ibrutinib studied in …STUDIED_INderived200 of 285show all (up to 200) |
|---|
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma,T-Cell/Histiocyte-Rich Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03462719Phase 3 · active not recruiting A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02649387Phase 2 · completed Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05963074Phase 2 · active not recruiting A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06299540recruiting Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02940301Phase 2 · active not recruiting Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840602Phase 2 · recruiting Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoplasmacytic Lymphoma,Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136559Phase 3 · recruiting A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02537613Phase 1 · active not recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02436707Phase 2 · active not recruiting Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446236Phase 1 · active not recruiting Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02629809Phase 2 · active not recruiting Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03535350Phase 1 · active not recruiting Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma · 285 trials list this drug (85 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01841723Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia · 285 trials list this drug (85 active) | — | — | Hairy Cell Leukemia,Hairy Cell Leukemia Variant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05998642Phase 2 · recruiting Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma · 285 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma,Grade 3 Follicular Lymphoma,Grade 1 Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910583Phase 2 · completed Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) · 285 trials list this drug (85 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03964090Phase 2 · active not recruiting Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · 285 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03021460Phase 1 · completed Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery · 285 trials list this drug (85 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01886872Phase 3 · active not recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02048813Phase 3 · active not recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02203526Phase 1 · active not recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · 285 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03701282Phase 3 · active not recruiting Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737981Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04477486Phase 2 · completed Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802590Phase 2 · active not recruiting Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02477696Phase 3 · active not recruiting Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02160015Phase 1 · active not recruiting Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · 285 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma,Indolent Non-Hodgkin Lymphoma,Splenic Marginal Zone Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254743Phase 3 · recruiting A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 285 trials list this drug (85 active) | — | — | Leukemia,Lymphoid Leukemia,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440567Phase 1 · completed Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Mantle Cell Lymphoma,Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02581930Phase 2 · completed Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma · 285 trials list this drug (85 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756897Phase 2 · active not recruiting Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03220022Phase 1 · active not recruiting Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas · 285 trials list this drug (85 active) | — | — | AIDS-Related Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03128879Phase 2 · active not recruiting Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804686Phase 3 · recruiting A Long-term Extension Study of PCI-32765 (Ibrutinib) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443077Phase 3 · active not recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07738887Phase 2 · not yet recruiting Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03478514Phase 2 · active not recruiting Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04212013Phase 3 · active not recruiting A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma · 285 trials list this drug (85 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · 285 trials list this drug (85 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Grade 3 Follicular Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02251548Phase 2 · active not recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03282396Phase 2 · active not recruiting Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07082868Phase 1 · recruiting A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) · 285 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma,Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01880567Phase 2 · active not recruiting Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283720Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01829568Phase 1 · active not recruiting Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03323151Phase 1/Phase 2 · completed A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · 285 trials list this drug (85 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02007044Phase 2 · active not recruiting Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02427451Phase 1/Phase 2 · active not recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03447808Phase 1 · completed Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02242097Phase 2 · completed Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02997761Phase 2 · completed Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia · 285 trials list this drug (85 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672173Phase 2 · active not recruiting Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03960840Phase 1/Phase 2 · active not recruiting Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL · 285 trials list this drug (85 active) | — | — | Acute Lymphoblastic Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159755Phase 1 · active not recruiting Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02427620Phase 2 · active not recruiting Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma,Blastoid Variant Mantle Cell Lymphoma,Pleomorphic Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06271616Phase 2 · terminated Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphatic System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02787369Phase 1 · active not recruiting ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03710772Phase 2 · active not recruiting Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01955499Phase 1 · active not recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04263480Phase 2 · active not recruiting Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04273139Phase 2 · active not recruiting Ibrutinib + Venetoclax in Untreated WM · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03506373Phase 2 · terminated Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04608318Phase 3 · active not recruiting Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01500733Phase 2 · active not recruiting PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03479268Phase 1 · active not recruiting Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | B-Cell Prolymphocytic Leukemia,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03328078Phase 1/Phase 2 · recruiting CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514083Phase 2 · active not recruiting A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01589302Phase 2 · active not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Prolymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03697512Phase 2 · active not recruiting MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas · 285 trials list this drug (85 active) | — | — | Splenic Marginal Zone Lymphoma,Marginal Zone Lymphoma,Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02518555Phase 2 · completed Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682641Phase 2 · active not recruiting Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02947347Phase 3 · completed Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03514017Phase 2 · terminated Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04421560Phase 1/Phase 2 · recruiting Pembrolizumab, Ibrutinib and Rituximab in PCNSL · 285 trials list this drug (85 active) | — | — | Malignant Neoplasm,Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03581942Phase 1/Phase 2 · completed Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) · 285 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03513562Phase 2 · active not recruiting Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377578Phase 3 · recruiting A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315326Phase 1/Phase 2 · completed Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) · 285 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03204188Phase 2 · completed Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357676Phase 1/Phase 2 · recruiting Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03703167Phase 1 · completed Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) · 285 trials list this drug (85 active) | — | — | Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294641Phase 2 · completed Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05106296Phase 1 · recruiting Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer · 285 trials list this drug (85 active) | — | — | Glioblastoma,Medulloblastoma,Ependymoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211336Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System · 285 trials list this drug (85 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03702725Phase 1 · completed Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma · 285 trials list this drug (85 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03708003Phase 2 · terminated Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL · 285 trials list this drug (85 active) | — | — | Leukemia,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04230304Phase 2 · terminated Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07052695Phase 1/Phase 2 · recruiting Mosunetuzumab for CLL MRD Clearance · 285 trials list this drug (85 active) | — | — | Leukemia,Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02666898Phase 2 · completed Phase II Trial GA101 Inbrutinib B CLL · 285 trials list this drug (85 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734198Phase 2 · active not recruiting Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02827617completed Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03229200Phase 4 · active not recruiting Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. · 285 trials list this drug (85 active) | — | — | Solid Neoplasm,B-Cell Malignant Neoplasm,Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05105841Phase 2 · completed Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564052Phase 2 · completed A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607772Phase 1/Phase 2 · withdrawn Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04446962Phase 1/Phase 2 · active not recruiting LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) · 285 trials list this drug (85 active) | — | — | Lymphoma,Primary Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315768Phase 1/Phase 2 · completed Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07169565Phase 1 · not yet recruiting Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03207555Phase 2 · completed Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424122Phase 1 · completed INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) · 285 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04876092Phase 1 · completed A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL · 285 trials list this drug (85 active) | — | — | Leukemia,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015792Phase 1 · terminated Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant · 285 trials list this drug (85 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03112174Phase 3 · completed Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02956382Phase 1/Phase 2 · completed Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01776840Phase 3 · completed A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02303392Phase 1 · completed Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia,Small Lymphocytic Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02329847Phase 1/Phase 2 · completed A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03190330Phase 4 · completed A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion · 285 trials list this drug (85 active) | — | — | Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042376Phase 4 · completed A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04062448Phase 2 · completed A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04685915Phase 2 · withdrawn Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02899078Phase 1/Phase 2 · completed Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer · 285 trials list this drug (85 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03400176Phase 1 · terminated VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02966730early Phase 1 · terminated Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03939182Phase 1 · completed Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04494503Phase 1/Phase 2 · recruiting Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734016Phase 3 · completed A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02744612Phase 2 · completed Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03770416Phase 2 · completed Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma · 285 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04781855Phase 1 · withdrawn Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02824029Phase 2 · completed Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01855750Phase 3 · completed A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01833039approved for marketing An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02743546Phase 1 · withdrawn Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma · 285 trials list this drug (85 active) | — | — | Leukemia,Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03476655completed Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India · 285 trials list this drug (85 active) | — | — | Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02232386Phase 2 · completed Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02643667Phase 2 · completed Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer · 285 trials list this drug (85 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02207062Phase 2 · completed Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02863718Phase 3 · completed Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950051Phase 3 · completed Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03379428Phase 1/Phase 2 · active not recruiting Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer · 285 trials list this drug (85 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03153202Phase 1/Phase 2 · active not recruiting Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02268851Phase 1 · completed A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03053440Phase 3 · completed A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927964Phase 1/Phase 2 · completed TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma,Mantle Cell Lymphoma,Grade 1 Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02692248Phase 2 · completed Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02532257Phase 2 · completed Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma · 285 trials list this drug (85 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136497Phase 1 · terminated A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01724346Phase 3 · completed Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04274738Phase 1 · completed A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05864742Phase 2 · active not recruiting Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03422393Phase 1 · active not recruiting Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06482684Phase 2 · recruiting CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03225716Phase 1 · terminated A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03310619Phase 1/Phase 2 · completed A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies · 285 trials list this drug (85 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02420912Phase 2 · completed Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03525925Phase 1 · completed Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors · 285 trials list this drug (85 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02451111Phase 2 · terminated Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma · 285 trials list this drug (85 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02636322Phase 2 · completed Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03684694Phase 1/Phase 2 · terminated Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03399513Phase 2 · completed Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439006Phase 1 · completed Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm,Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05694312Phase 2 · recruiting Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02599324Phase 1/Phase 2 · completed Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors · 285 trials list this drug (85 active) | — | — | Urothelial Carcinoma,Colorectal Adenocarcinoma,Gastric Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02733042Phase 1/Phase 2 · completed A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02352558Phase 1 · completed A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02321540Phase 1/Phase 2 · completed A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer · 285 trials list this drug (85 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02869633Phase 2 · completed Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant · 285 trials list this drug (85 active) | — | — | Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03679624Phase 2 · terminated Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03093831Phase 2 · terminated Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02874404Phase 2 · completed TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04758975Phase 2 · recruiting Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02471391Phase 2 · unknown ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03267186Phase 2 · completed Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant · 285 trials list this drug (85 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03219047early Phase 1 · completed Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04016805Phase 2 · terminated Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02760485Phase 1/Phase 2 · completed A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03145480Phase 2 · terminated Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients · 285 trials list this drug (85 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02309580Phase 1 · completed Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma · 285 trials list this drug (85 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05431179Phase 3 · withdrawn A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522284Phase 1/Phase 2 · unknown PRECISE CURATE.AI Pilot Clinical Trial · 285 trials list this drug (85 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03121534Phase 2 · terminated Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation · 285 trials list this drug (85 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03876028Phase 1 · terminated Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients · 285 trials list this drug (85 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02758665Phase 2 · completed Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL · 285 trials list this drug (85 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03873493Phase 2 · completed A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia · 285 trials list this drug (85 active) | — | — | Malignant Neoplasm,Leukemia,T-Cell Prolymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03877055Phase 1/Phase 2 · completed A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02604511Phase 2 · completed Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing · 285 trials list this drug (85 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02703272Phase 3 · terminated A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma · 285 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02013128Phase 1/Phase 2 · completed Ublituximab + Ibrutinib in Select B-cell Malignancies · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756247Phase 1 · completed A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma · 285 trials list this drug (85 active) | — | — | Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02553941Phase 1 · completed Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome · 285 trials list this drug (85 active) | — | — | Myelodysplastic Syndrome,Secondary Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03425591completed A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice · 285 trials list this drug (85 active) | — | — | Leukemia,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01886859Phase 1 · completed Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | B-Cell Prolymphocytic Leukemia,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03280160Phase 2 · unknown Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665115Phase 2 · withdrawn Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) · 285 trials list this drug (85 active) | — | — | B-Cell Neoplasm,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332498Phase 1/Phase 2 · completed Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers · 285 trials list this drug (85 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02301156Phase 3 · completed Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02623010Phase 2 · unknown Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma · 285 trials list this drug (85 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02542514Phase 2 · completed Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma · 285 trials list this drug (85 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04514393Phase 2 · unknown Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma · 285 trials list this drug (85 active) | — | — | Non-Hodgkin Lymphoma,Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02356458Phase 1/Phase 2 · terminated Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma · 285 trials list this drug (85 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209621Phase 2 · terminated Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 285 trials list this drug (85 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |